Mittleman Eye among the first in Palm Beach County to offer the Alcon PanOptix Lens
Alcon, the global leader in eye care, introduces the FDA-approved AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL), the first and only trifocal lens for U.S. patients undergoing cataract surgery. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while significantly reducing the need for glasses after surgery.
What is PanOptix®?
The AcrySof® IQ PanOptix® Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the AcrySof® IQ PanOptix® Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. There is a chance that you still may need glasses for distance, intermediate, and/or near vision. You will get the full benefit of the AcrySof® IQ PanOptix® Trifocal IOL when it is placed in both eyes. Please discuss with your eye doctor whether this is the right IOL for you.
How Does PanOptix Work?
PanOptix utilizes Alcon’s proprietary, non-apodized ENLIGHTEN (ENhanced LIGHT ENergy) Optical Technology, which optimizes intermediate vision without compromising on near and distance.
Alcon created this patented technology as a solution to improve on the limitations of traditional trifocal IOLs, which typically have an intermediate focal point that isn’t comfortable for most patients.
PanOptix offers an excellent intermediate vision range and is designed to improve vision after cataract surgery for today’s active lifestyles, from viewing mobile devices to high-quality distance vision in a range of lighting conditions.
With the PanOptix® Lens, you can seize every day.
Without cataracts. Without hesitation. Without holding back.
- PanOptix delivers an exceptional combination of near, intermediate and distance vision and substantially reduces the need for glasses
- More than ninety-nine percent of PanOptix patients in the FDA clinical study said they would choose the same lens again
- U.S. surgeon training and patient awareness efforts to begin immediately with ramp up into early 2020
What Are Patients Saying?
The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S. With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.
More than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024. The presbyopia-correcting IOL market is expected to grow 60 percent by the end of 2024.
Mittleman Eye is proud to be one of the first ophthalmologists in Palm Beach Couty to offer this latest technology. Ask our doctors for more information about the PanOptix Lens and how it may benefit you.